

		Express Mail No.	EL563390460US
		Date	August 23, 2001
<p>PRELIMINARY AMENDMENT</p> <p>Address to: BOX PATENT APPLICATION Assistant Commissioner for Patents Washington, D.C. 20231</p>	Attorney Docket	UCAL082CON	
	First Named Inventor	ROSS	
	Application Number	To Be Assigned	
	Filing Date	Herewith (August 23, 2001)	
	Group Art Unit	To Be Assigned	
	Examiner Name	To Be Assigned	
	Title: "TREATMENT OF HEART FAILURE WITH GROWTH HORMONE"		

Sir:

Prior to examination, please amend the application as follows:

IN THE CLAIMS:

Please cancel claims 1-16.

Please add new claims as follows:

17. (New) A method for treating heart failure in a subject, comprising:

- a) administering an angiotensin II (AT₁) receptor inhibitor to said subject for a first period beginning at about the time of a myocardial infarction;
- b) reducing administration of said angiotensin II (AT₁) receptor inhibitor after said initial period; and
- c) administering a growth hormone during a second period beginning after said reducing administration of said AT₁ receptor inhibitor.

18. (New) The method of claim 17, wherein said first period has a duration of about 10 to 12 weeks.

19. (New) The method of claim 17, wherein the AT₁ receptor inhibitor is administered at least once daily.

20. (New) The method of claim 17, wherein AT₁ receptor inhibitor administration is discontinued following said first period.

21. (New) The method of claim 17, wherein said AT₁ receptor inhibitor comprises losartan.

22. (New) The method of claim 17, wherein said growth hormone is administered for about two weeks to about three months.

23. (New) The method of claim 17, wherein said reducing of AT₁ receptor inhibitor allows

for a favorable physiologic hypertrophic effect from said growth hormone.

24. (New) A method of treating heart failure in a subject, comprising;

a) administering an angiotensin II (AT₁) receptor inhibitor to said subject over a first period beginning about the time of an ischemic event, and said first period continuing for a sufficient amount of time to substantially permit favorable left ventricular remodeling or limit unfavorable ventricular remodeling;

b) decreasing said administering of AT₁ receptor inhibitor at a time approximately after said ventricular remodeling; and

c) administering a growth hormone to said subject during a second period beginning at a time approximately after said ventricular remodeling.

25. (New) The method of claim 24, wherein administering said AT₁ receptor inhibitor is discontinued at about the time administering said growth hormone begins.

26. (New) The method of claim 24, wherein the angiotensin II (AT₁) receptor inhibitor is administered at least once daily.

27. (New) The method of claim 24, wherein administration of said AT₁ receptor inhibitor is discontinued at about the time administering said growth hormone begins.

28. (New) The method of claim 24, wherein said administration of said AT₁ receptor inhibitor following said ventricular remodeling is decreased prior to the end of said first period.

29. (New) The method of claim 24, wherein said AT₁ receptor inhibitor comprises losartan.

30. (New) The method of claim 24, wherein said growth hormone is human growth hormone.

31. (New) The method of claim 24, wherein said AT₁ receptor inhibitor is administered beginning within seven days of said ischemic event.

32. (New) The method of claim 24, wherein said AT₁ receptor inhibitor is administered for about 8 to about 12 weeks.

33. (New) The method of claim 24, wherein said AT₁ receptor inhibitor is administered for about 10 weeks.

34. (New) The method of claim 24, wherein said growth hormone is administered for about two weeks to about three months.

35. (New) The method of claim 24, wherein a second administration of a composition comprising AT₁ receptor inhibitor is administered for a time following said growth hormone administration.

36. (New) The method of claim 35, wherein growth hormone is administered following said second administration of AT₁ receptor inhibitor.

37. (New) The method of claim 24, wherein decreasing said administering of AT₁ receptor inhibitor allows for a favorable physiologic hypertrophic effect from said growth hormone.

No new matter is introduced by these amendments.

REMARKS

Originally filed claims 1-16 have been cancelled and new claims 17-37 have been added to more distinctly point out and describe the invention disclosed in the application filed herewith.

This amendment is being filed with an Appendix of Pending Claims and a transmittal letter/fee sheet. In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that extensions or other relief is required and/or fees are due, applicants petition for any required relief including extensions of time and authorize the Commissioner to charge our Deposit Account No. 50-0815 for any fees due in connection with the filing of this document.

Respectfully submitted,

By: 
Kathleen S. Hall, Reg. No. 44,143

Date: August 23, 2001

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

**APPENDIX OF PENDING CLAIMS FOR:
“TREATMENT OF HEART FAILURE WITH GROWTH HORMONE”
FILED HEREWITH (AUGUST 23, 2001)**

17. (New) A method for treating heart failure in a subject, comprising:

- a) administering an angiotensin II (AT₁) receptor inhibitor to said subject for a first period beginning at about the time of a myocardial infarction;
- b) reducing administration of said angiotensin II (AT₁) receptor inhibitor after said initial period; and
- c) administering a growth hormone during a second period beginning after said reducing administration of said AT₁ receptor inhibitor.

18. (New) The method of claim 17, wherein said first period has a duration of about 10 to 12 weeks.

19. (New) The method of claim 17, wherein the AT₁ receptor inhibitor is administered at least once daily.

20. (New) The method of claim 17, wherein AT₁ receptor inhibitor administration is discontinued following said first period.

21. (New) The method of claim 17, wherein said AT₁ receptor inhibitor comprises losartan.

22. (New) The method of claim 17, wherein said growth hormone is administered for about two weeks to about three months.

23. (New) The method of claim 17, wherein said reducing of AT₁ receptor inhibitor allows for a favorable physiologic hypertrophic effect from said growth hormone.

24. (New) A method of treating heart failure in a subject, comprising;

a) administering an angiotensin II (AT₁) receptor inhibitor to said subject over a first period beginning about the time of an ischemic event, and said first period continuing for a sufficient amount of time to substantially permit favorable left ventricular remodeling or limit unfavorable ventricular remodeling;

b) decreasing said administering of AT₁ receptor inhibitor at a time approximately after said ventricular remodeling; and

c) administering a growth hormone to said subject during a second period beginning at a time approximately after said ventricular remodeling.

25. (New) The method of claim 24, wherein administering said AT₁ receptor inhibitor is discontinued at about the time administering said growth hormone begins.

26. (New) The method of claim 24, wherein the angiotensin II (AT₁) receptor inhibitor is administered at least once daily.

27. (New) The method of claim 24, wherein administration of said AT₁ receptor inhibitor is discontinued at about the time administering said growth hormone begins.

28. (New) The method of claim 24, wherein said administration of said AT₁ receptor inhibitor following said ventricular remodeling is decreased prior to the end of said first period.

29. (New) The method of claim 24, wherein said AT₁ receptor inhibitor comprises losartan.

30. (New) The method of claim 24, wherein said growth hormone is human growth hormone.

31. (New) The method of claim 24, wherein said AT₁ receptor inhibitor is administered

beginning within seven days of said ischemic event.

32. (New) The method of claim 24, wherein said AT₁ receptor inhibitor is administered for about 8 to about 12 weeks.

33. (New) The method of claim 24, wherein said AT₁ receptor inhibitor is administered for about 10 weeks.

34. (New) The method of claim 24, wherein said growth hormone is administered for about two weeks to about three months.

35. (New) The method of claim 24, wherein a second administration of a composition comprising AT₁ receptor inhibitor is administered for a time following said growth hormone administration.

36. (New) The method of claim 35, wherein growth hormone is administered following said second administration of AT₁ receptor inhibitor.

37. (New) The method of claim 24, wherein decreasing said administering of AT₁ receptor inhibitor allows for a favorable physiologic hypertrophic effect from said growth hormone.